

October 20, 2014

GlaxoSmithKline K.K.
Sumitomo Dainippon Pharma Co., Ltd.

**Announcement of termination of co-promotion of anti-depressant, *Paxil*[®]
*CR Tablets***

GlaxoSmithKline K.K. (President: Philippe Fauchet, Head Office: Shibuya-ku, Tokyo) and Sumitomo Dainippon Pharma Co., Ltd. (President: Masayo Tada, Head Office: Chuo-ku, Osaka) announced today that the companies have reached an agreement to terminate the co-promotion of GlaxoSmithKline K.K.'s anti-depressant *Paxil*[®] *CR Tablets 12.5mg* and *Paxil*[®] *CR Tablets 25mg* (paroxetine hydrochloride hydrate, hereinafter referred to as *Paxil*[®] *CR*, CR stands for Controlled Release) as of end of December 2014.

The co-promotion activity by the 2 companies was started in April 2012, with the objective of accelerating the providing and collecting of proper prescribing information on *Paxil*[®] *CR*, so that this medication can support patients suffering from depression.

From January 2015, GlaxoSmithKline K.K. will solely be responsible for providing information on *Paxil*[®] *CR*.

GlaxoSmithKline K.K. and Sumitomo Dainippon Pharma Co., Ltd. will continue to contribute to medicine through providing and collecting of proper prescribing information of individual products.

Contacts:

GlaxoSmithKline K.K.
Corporate Communications
TEL: +81-3-5786-5030
URL: <http://glaxosmithkline.co.jp/>

Sumitomo Dainippon Pharma Co., Ltd.
Corporate Communications
TEL: +81-6-6203-1407 (Osaka)
+81-3-5159-3300 (Tokyo)
URL: <http://www.ds-pharma.com/>